Loading...
XJPX4543
Market cap28bUSD
Dec 20, Last price  
3,027.00JPY
1D
-0.62%
1Q
12.84%
Jan 2017
40.30%
Name

Terumo Corp

Chart & Performance

D1W1MN
XJPX:4543 chart
P/E
42.23
P/S
4.87
EPS
71.67
Div Yield, %
0.71%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
8.99%
Revenues
921.86b
+12.39%
230,003,000,000247,048,000,000276,439,000,000306,381,000,000302,746,000,000316,009,000,000328,214,000,000386,686,000,000402,294,000,000467,359,000,000489,506,000,000525,026,000,000514,164,000,000587,775,000,000599,481,000,000628,897,000,000613,842,000,000703,303,000,000820,209,000,000921,863,000,000
Net income
106.37b
+19.09%
27,134,000,00032,457,000,00037,232,000,00043,382,000,00036,878,000,00040,721,000,00032,338,000,00024,167,000,00047,014,000,00034,096,000,00038,470,000,00050,676,000,00054,225,000,00091,295,000,00079,470,000,00085,211,000,00077,268,000,00088,813,000,00089,325,000,000106,374,000,000
CFO
146.33b
+24.50%
43,725,000,00043,380,000,00043,123,000,00069,683,000,00031,615,000,00067,352,000,00046,828,000,00056,200,000,00050,270,000,00096,259,000,00073,110,000,00080,303,000,00080,862,000,000114,562,000,00093,571,000,000117,479,000,000121,485,000,000141,467,000,000117,536,000,000146,330,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 05, 2025

Profile

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.
URL
https://www.terumo.co.jp/
IPO date
Jun 21, 1982
Employees
30,207
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
921,863,000
12.39%
820,209,000
16.62%
703,303,000
14.57%
Cost of revenue
785,807,000
801,418,000
668,349,000
Unusual Expense (Income)
NOPBT
136,056,000
18,791,000
34,954,000
NOPBT Margin
14.76%
2.29%
4.97%
Operating Taxes
34,455,000
26,811,000
25,687,000
Tax Rate
25.32%
142.68%
73.49%
NOPAT
101,601,000
(8,020,000)
9,267,000
Net income
106,374,000
19.09%
89,325,000
0.58%
88,813,000
14.94%
Dividends
(32,010,000)
(27,900,000)
(23,455,000)
Dividend yield
0.79%
0.52%
0.42%
Proceeds from repurchase of equity
(11,111,000)
(50,085,000)
(3,000)
BB yield
0.27%
0.93%
0.00%
Debt
Debt current
164,220,000
11,223,000
1,121,000
Long-term debt
133,678,000
248,645,000
252,151,000
Deferred revenue
1,518,000
34,469,000
36,221,000
Other long-term liabilities
16,289,000
9,108,000
9,817,000
Net debt
52,766,000
11,152,000
1,845,000
Cash flow
Cash from operating activities
146,330,000
117,536,000
141,467,000
CAPEX
(60,727,000)
(72,173,000)
(74,105,000)
Cash from investing activities
(81,472,000)
(59,121,000)
(78,454,000)
Cash from financing activities
(62,079,000)
(86,559,000)
(70,879,000)
FCF
(53,482,000)
(85,416,000)
(48,931,000)
Balance
Cash
206,354,000
187,428,000
205,314,000
Long term investments
38,778,000
61,288,000
46,113,000
Excess cash
199,038,850
207,705,550
216,261,850
Stockholders' equity
1,287,774,000
2,024,051,000
1,898,007,000
Invested Capital
1,414,406,150
1,155,308,450
1,053,981,150
ROIC
7.91%
0.93%
ROCE
8.42%
1.37%
2.72%
EV
Common stock shares outstanding
1,488,403
1,501,871
1,513,322
Price
2,729.00
-23.64%
3,574.00
-4.03%
3,724.00
-6.88%
Market cap
4,061,852,920
-24.33%
5,367,687,140
-4.75%
5,635,610,562
-6.89%
EV
4,114,618,920
6,332,048,140
6,568,842,562
EBITDA
212,801,000
89,029,000
93,836,000
EV/EBITDA
19.34
71.12
70.00
Interest
2,775,000
4,016,000
2,961,000
Interest/NOPBT
2.04%
21.37%
8.47%